Effective and safe implementation of precision oncology for breast cancer is a vital strategy to improve patient outcomes, which relies on the application of reliable biomarkers. As ‘liquid biopsy’ and novel resource for biomarkers, exosomes provide a promising avenue for the diagnosis and treatment of breast cancer. Although several exosome-related databases have been developed, there is still lacking of an integrated database for exosome-based biomarker discovery. To this end, a comprehensive database ExoBCD (https://exobcd.liumwei.org) was constructed with the combination of robust analysis of four high-throughput datasets, transcriptome validation of 1191 TCGA cases and manual mining of 950 studies. In ExoBCD, approximately 20 900 annotation entries were integrated from 25 external sources and 306 exosomal molecules (49 potential biomarkers and 257 biologically interesting molecules). The latter could be divided into 3 molecule types, including 121 mRNAs, 172 miRNAs and 13 lncRNAs. Thus, the well-linked information about molecular characters, experimental biology, gene expression patterns, overall survival, functional evidence, tumour stage and clinical use were fully integrated. As a data-driven and literature-based paradigm proposed of biomarker discovery, this study also demonstrated the corroborative analysis and identified 36 promising molecules, as well as the most promising prognostic biomarkers, IGF1R and FRS2. Taken together, ExoBCD is the first well-corroborated knowledge base for exosomal studies of breast cancer. It not only lays a foundation for subsequent studies but also strengthens the studies of probing molecular mechanisms, discovering biomarkers and developing meaningful clinical use.

中文翻译：

---

ExoBCD：乳腺癌外泌体生物标志物发现的综合数据库。

有效和安全地实施乳腺癌精准肿瘤学是改善患者预后的重要策略，这依赖于可靠生物标志物的应用。作为“液体活检”和生物标志物的新资源，外泌体为乳腺癌的诊断和治疗提供了有希望的途径。尽管已经开发了几个与外泌体相关的数据库，但仍然缺乏用于基于外泌体的生物标志物发现的综合数据库。为此，结合四个高通量数据集的稳健分析、1191 个 TCGA 案例的转录组验证和 950 项研究的人工挖掘，构建了一个综合数据库 ExoBCD (https://exobcd.liumwei.org)。在 ExoBCD 中，从 25 个外部来源和 306 个外泌体分子（49 个潜在生物标志物和 257 个生物学上感兴趣的分子）整合了大约 20 900 个注释条目。后者可分为3种分子类型，包括121个mRNAs、172个miRNAs和13个lncRNAs。因此，关于分子特征、实验生物学、基因表达模式、总生存期、功能证据、肿瘤分期和临床应用的紧密联系的信息被完全整合。作为生物标志物发现的数据驱动和基于文献的范式，本研究还证明了确证分析并确定了 36 个有希望的分子，以及最有希望的预后生物标志物，关于分子特征、实验生物学、基因表达模式、总生存期、功能证据、肿瘤分期和临床应用的相关信息被完全整合。作为生物标志物发现的数据驱动和基于文献的范式，本研究还证明了确证分析并确定了 36 个有希望的分子，以及最有希望的预后生物标志物，关于分子特征、实验生物学、基因表达模式、总生存期、功能证据、肿瘤分期和临床应用的相关信息被完全整合。作为生物标志物发现的数据驱动和基于文献的范式，本研究还证明了确证分析并确定了 36 个有希望的分子，以及最有希望的预后生物标志物，IGF1R和FRS2。综上所述，ExoBCD 是第一个经过充分证实的乳腺癌外泌体研究知识库。它不仅为后续研究奠定了基础，而且加强了探索分子机制、发现生物标志物和开发有意义的临床应用的研究。